Veeva Systems

Veeva Systems Inc. (VEEV) (Q4FY24) – Streamlining clinical trials for a faster future

Highlights of the report

Veeva Systems, a leading provider of cloud-based solutions for the global life sciences industry has successfully rolled out the Veeva Compass Suite, a comprehensive suite of commercial data products designed to modernize the industry’s data infrastructure.

Veeva Systems (VEEV) Equity Report Q4FY24

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.

 

CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).

 

Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions.

VEEVA’s revenue has increased by 12% to $630.6mn in Q4FY24 from $563.4mn in Q4FY23.

Over the past 3 months, Veeva Systems stock generated positive returns of 12.70% where the stock price increased to $214.73 as on April 5th, 2024 from $190.54 in Jan 8, 2024.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

Report details

Veeva Systems Inc. (VEEV) (Q4FY24) – Streamlining clinical trials for a faster future

Price

$312.00

Company Reports

Sector Reports